Moderna says Omicron-specific booster generates strong immune response
June 8
Moderna Inc said on Wednesday its COVID-19 vaccine booster that targets both the original coronavirus strain and Omicron produced a better immune response against the variant than its original vaccine.
The booster raised virus-neutralising antibodies by eight-fold in a study. The vaccine was generally well-tolerated, with side effects comparable to a booster dose of mRNA-1273 at the 50 micrograms level.
“We are submitting our preliminary data and analysis to regulators with the hope that the Omicron-containing bivalent booster will be available in the late summer,” Chief Executive Stephane Bancel said in a statement.
Share of Moderna were up 2% in premarket trading.
Unlock Exclusive Insights with The Tribune Premium
Take your experience further with Premium access.
Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Already a Member? Sign In Now
